GNA11 Q209L
|
Uveal Melanoma
|
GNA11 Q209L
|
Uveal Melanoma
|
IDE196 Sensitive: C3 – Early Trials
|
IDE196 Sensitive: C3 – Early Trials
|
GNA11 Q209L
|
Uveal Melanoma
|
GNA11 Q209L
|
Uveal Melanoma
|
selumetinib Sensitive: C3 – Early Trials
|
selumetinib Sensitive: C3 – Early Trials
|
GNA11 Q209L
|
Uveal Melanoma
|
GNA11 Q209L
|
Uveal Melanoma
|
REC-4881 Sensitive: D – Preclinical
|
REC-4881 Sensitive: D – Preclinical
|
GNA11 Q209L
|
Uveal Melanoma
|
GNA11 Q209L
|
Uveal Melanoma
|
trametinib + GSK2126458 Sensitive: D – Preclinical
|
trametinib + GSK2126458 Sensitive: D – Preclinical
|
GNA11 Q209L
|
Uveal Melanoma
|
GNA11 Q209L
|
Uveal Melanoma
|
trametinib + hydroxychloroquine Sensitive: D – Preclinical
|
trametinib + hydroxychloroquine Sensitive: D – Preclinical
|